Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
A2Z Cust2Mate Q1 2026 Earnings Call - Transitioning from Pilots to $195M Backlog with New Retail Media Layer
A2Z Cust2Mate is shedding its pilot-stage label and entering a structured, multi-phase commercial deployment cycle. The company reported $3.3 million in Q1 revenue, driven by a 114% year-over-year inc...
- Q1 2026 revenue hit $3.3 million, marking a 114% year-over-year increase as the company shifts from pilot validation to scaled commercial deployment.
- The contracted backlog has expanded dramatically to over $195 million, representing more than 19,000 Smart Carts scheduled for global deployment through the end of 2027.
- A2Z secured a $30 million contract-backed, non-dilutive bank credit facility. This capital is directly tied to customer contracts and deployment schedules, providing structural funding for working capital needs.
- +9 more takeaways
Harvard Bioscience Q1 2026 Earnings Call - NPI Portfolio Drives Margin Expansion and Pharma Shift
Harvard Bioscience delivered a steady Q1 2026, with revenue of $20.8 million landing in line with guidance. The real story is structural: the company is successfully pivoting from a traditional academ...
- Revenue of $20.8 million landed squarely within the $20 million to $22 million guidance range, though it represents a year-over-year decline driven by weak academic and APAC distributor sales.
- Adjusted gross margin expanded 300 basis points year-over-year to 59%, the high end of guidance, fueled by a mix shift toward higher-margin new product innovations (NPI).
- NPI products, including Mesh MEA, BTX, and SoHo Telemetry, grew to over 12% of total revenue, up from approximately 4% in Q1 2025, and are expected to deliver double-digit growth for the full year.
- +7 more takeaways
Super League Gaming Q1 2026 Earnings Call - Misfits Ads Acquisition Drives Margin Expansion and Cross-Channel Momentum
Super League Gaming delivered its first quarter of 2026 results with a clear pivot from stabilization to execution. Gross revenue rose to $3.3 million, up from $2.7 million a year ago, while gross mar...
- Gross revenue for Q1 2026 increased to $3.3 million, up from $2.7 million in the prior year quarter, signaling an early establishment of a higher revenue baseline.
- Gross margin expanded to 36% in Q1 from 32% in Q4 2025, driven by a shift toward turnkey packages and higher-margin media solutions.
- The company closed its acquisition of the Misfits Ads business, adding profitable programmatic revenue, proprietary technology, and an expanded brand pipeline.
- +7 more takeaways
Lifeward Q1 2026 Earnings Call - Oratech Acquisition and Profitability Path
Lifeward reported a Q1 2026 revenue decline to $3.9 million from $5 million, driven by temporary AlterG shipment disruptions tied to working capital constraints and manufacturing transitions. However,...
- Lifeward closed its equity-based acquisition of Oratech, gaining access to a protein oral delivery platform including ORMD-0801 oral insulin, with clinical program management retained by Oramed to minimize near-term operational burden.
- Q1 2026 revenue fell to $3.9 million from $5 million, primarily due to temporary AlterG shipment delays linked to working capital constraints and manufacturing transition disruptions.
- ReWalk personal exoskeleton revenue grew 11% year-over-year to $1.6 million, supported by expanded reimbursement access with Medicare Advantage insurers like Aetna, Humana, and UnitedHealthcare.
- +7 more takeaways
Silicom Ltd Q1 2026 Earnings Call - 33% Revenue Growth Accelerates as Design Wins and AI Inference Strategy Gain Traction
Silicom delivered a standout first quarter of 2026, with revenues jumping 33% year-over-year to $19.1 million, significantly outpacing the company's own guidance and marking the second consecutive qua...
- Revenues reached $19.1 million in Q1 2026, a 33% year-over-year increase that crushed the original 18% guidance midpoint and doubled the 17% growth rate from the prior quarter.
- Full-year 2026 revenue guidance was raised to $82 million-$83 million, implying approximately 33% year-over-year growth, while Q2 guidance points to $20 million-$21 million in revenue.
- The company has secured four design wins in the first quarter of 2026, halfway toward its annual target of 7-9 wins, with momentum expected to carry into 2027 and beyond.
- +7 more takeaways
Cadre Holdings Q1 2026 Earnings Call - Record Backlog and M&A Fuel Growth
Cadre Holdings delivered a strong start to 2026, with Q1 net sales rising 19% year-over-year to $155.4 million and a record order backlog of $355 million. The growth was driven by robust demand across...
- Q1 2026 net sales grew 19% year-over-year to $155.4 million, reflecting strong demand across public safety and nuclear markets.
- Record order backlog reached $355 million, an increase of $166 million from Q4 2025, driven by organic growth and acquisitions.
- Organic backlog growth of $108 million included an $87 million contract for Blast Attenuation Seats with General Dynamics European Land Systems.
- +7 more takeaways
Edible Garden Incorporated 2026 Q1 Earnings Call - RTD Pivot Drives 22.9% Revenue Growth Despite Operating Loss
Edible Garden reported a 22.9% year-over-year revenue increase to $3.3 million in Q1 2026, driven by strong cut herb sales (up 45.9%), international expansion (up 50%), and growth in vitamins and cond...
- Revenue increased 22.9% year-over-year to $3.3 million, driven by cut herb sales growth of 45.9% and new accounts like Kroger and Weis Markets.
- Cut herb sales remain the core revenue driver, representing 40-50% of the business, but management is actively shifting focus to higher-margin categories.
- International sales surged 50% year-over-year, primarily fueled by continued expansion with PriceSmart in the Caribbean and South America.
- +12 more takeaways
H World Group Q1 2026 Earnings Call - Margin Expansion Driven by Asset-Light Shift and Overseas Pullback
H World Group delivered another quarter of disciplined, high-quality growth in Q1 2026, with group revenue up 11.1% YoY to CNY 6.0 billion and adjusted EBITDA surging 24.2% to CNY 1.9 billion. The mar...
- Group revenue grew 11.1% YoY to CNY 6.0 billion, while adjusted EBITDA surged 24.2% YoY to CNY 1.9 billion, with the margin expanding 330 basis points to 31.0%.
- Adjusted net income jumped 38.6% YoY to CNY 1.1 billion, reflecting the structural profitability uplift from the asset-light franchise and management business.
- The asset-light M&F segment drove the margin expansion, with revenue rising 20.3% YoY to CNY 3.0 billion and gross operating profit climbing 20.7% to CNY 1.9 billion.
- +7 more takeaways
Telos Corporation Q1 2026 Earnings Call - 56% Revenue Growth and Accelerated Buybacks Signal Cash Conversion Machine
Telos Corporation delivered a violent start to 2026. Revenue jumped 56% year-over-year to $47.7 million, crushing the high end of guidance. Adjusted EBITDA margins exploded from 1.2% to 16.5%, proving...
- Revenue surged 56% year-over-year to $47.7 million, significantly beating the high end of the $44 million to $45 million guidance range.
- Adjusted EBITDA margins expanded dramatically from 1.2% in the prior year period to 16.5%, reaching $7.9 million and exceeding the high end of guidance.
- Free cash flow margins have now exceeded 12% for five consecutive quarters, demonstrating a structural improvement in working capital efficiency and cash generation.
- +7 more takeaways
SeaStar Medical Q1 2026 Earnings Call - QUELIMMUNE Revenue Surges 70% as Adult AKI Trial Enrolls 198 of 339 Patients
SeaStar Medical reported a 69% year-over-year increase in first-quarter 2026 net revenue, reaching $495,000, driven by the adoption of its QUELIMMUNE therapy in the pediatric acute kidney injury marke...
- First-quarter 2026 net revenue reached $495,000, a 69% increase from $293,000 in Q1 2025, driven by strong adoption of QUELIMMUNE therapy in pediatric acute kidney injury.
- Seven new hospitals adopted QUELIMMUNE in Q1 2026, bringing the total customer base to 17, with management targeting 15 new customers for the full year.
- Gross profit margin remained robust at over 90%, consistent with prior quarters, reflecting the high-margin nature of the commercialized product.
- +7 more takeaways